Biomarker & Intervention Discovery

Insomnia / Sleep Disorders

This page lists 9 druggable gene targets, 35 approved or trial-tested drug candidates and 15 recent clinical trials for Insomnia / Sleep Disorders, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionAcute insomnia (<3 months): 50-60% resolve spontaneously; chronic insomnia: only 20-25% spontaneous remission at 1…
Best-intervention remissionCognitive Behavioural Therapy for Insomnia (CBT-I): 70-80% response rate; 40-60% remission (normalised sleep); durable…
Gap sizeVery large — CBT-I is guideline-recommended as first-line but almost universally unavailable; medication is default
Primary barrieraccess/framing
Full remission profile →

Remission & chronicity

Spontaneous remission
Acute insomnia (<3 months): 50-60% resolve spontaneously; chronic insomnia: only 20-25% spontaneous remission at 1 year; persistent insomnia in 50-75% without treatment
Best-intervention remission
Cognitive Behavioural Therapy for Insomnia (CBT-I): 70-80% response rate; 40-60% remission (normalised sleep); durable at 6-24 months post-treatment; superior to sleep medication in long-term outcomes; digital CBT-I (Sleepio, Somryst) equivalent efficacy to in-person
Gap size
Very large — CBT-I is guideline-recommended as first-line but almost universally unavailable; medication is default
Primary barrier
access/framing
AASM and most sleep guidelines recommend CBT-I as first-line over medication for chronic insomnia; fewer than 1% of insomnia sufferers have access to a CBT-I trained therapist; digital CBT-I exists and works but is rarely prescribed; benzodiazepines and z-drugs continue to dominate prescribing despite guidelines against long-term use

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ADORA2A 283GABRA1 302GABRA2 264HCRTR1 233HCRTR2 245HRH1 374HTR2A 362MTNR1A 207MTNR1B 220
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CIFORADENANT ↓ inhibits Mechanistic
PSB36 ↓ inhibits Mechanistic
THEOPHYLLINE ↓ inhibits Mechanistic 28200.0 nM (EC50)
REGADENOSON ANHYDROUS ↑ activates Mechanistic
[3H]CGS 21680 ↑ activates Mechanistic
CV-1808 ↑ activates Mechanistic
MRS5151 ↑ activates Mechanistic
TOZADENANT ↓ inhibits Mechanistic
PBF-509 ↓ inhibits Mechanistic
CAFFEINE ↓ inhibits Mechanistic
ISTRADEFYLLINE ↓ inhibits Mechanistic
MRS1093 ↓ inhibits Mechanistic
SONEDENOSON ↑ activates Mechanistic
APADENOSON ↑ activates Mechanistic
MRS1086 ↓ inhibits Mechanistic
ST-1535 ↓ inhibits Mechanistic
(S)-PIA ↑ activates Mechanistic
MRE 3008F20 ↓ inhibits Mechanistic
BINODENOSON ↑ activates Mechanistic
PENTOXIFYLLINE ↓ inhibits Mechanistic
LUF7602 ↓ inhibits Mechanistic
ETRUMADENANT ↓ inhibits Mechanistic
MRS1088 ↓ inhibits Mechanistic
OXTRIPHYLLINE ↓ inhibits Mechanistic
ATL802 ↓ inhibits Mechanistic
DEXEFAROXAN ? unclear Mechanistic
CAFFEINE CITRATE ↓ inhibits Mechanistic
UK-432,097 ↑ activates Mechanistic
KF26777 ↓ inhibits Mechanistic
MRS1041 ↓ inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
XANTHINE AMINE CONGENER ↓ inhibits Mechanistic 18.4 nM (Ki)
DEFIBROTIDE ↑ activates Mechanistic
EVODENOSON ↑ activates Mechanistic
IMARADENANT ↓ inhibits Mechanistic
GALANGIN ↓ inhibits Mechanistic
LAS38096 ↓ inhibits Mechanistic
GS9667 ↑ activates Mechanistic
N(6)-CYCLOHEXYLADENOSINE ↑ activates Mechanistic
BVT.115959 ↑ activates Mechanistic

Showing top 40 of 283 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
PICROTOXIN ? unclear Mechanistic
THIAMYLAL SODIUM ~ modulates Mechanistic
GANAXOLONE ~ modulates Mechanistic
BUTOBARBITAL ? unclear Mechanistic
CHLORDIAZEPOXIDE ~ modulates Mechanistic
CLOBAZAM ~ modulates Mechanistic
CLORAZEPATE ? unclear Mechanistic
TPA023 ~ modulates Mechanistic
ZK-93423 ? unclear Mechanistic
FLUMAZENIL ~ modulates Mechanistic 3.3 nM (Ki)
AMOBARBITAL ? unclear Mechanistic
PAGOCLONE ~ modulates Mechanistic
OXAZEPAM ~ modulates Mechanistic
TETRAHYDRODEOXYCORTICOSTERONE ~ modulates Mechanistic
METHOHEXITAL ? unclear Mechanistic
CLONAZEPAM ~ modulates Mechanistic
[3H]GABAZINE ↓ inhibits Mechanistic
FLURAZEPAM ? unclear Mechanistic
METHARBITAL ~ modulates Mechanistic
LORAZEPAM ~ modulates Mechanistic
RO4938581 ~ modulates Mechanistic
SECOBARBITAL ? unclear Mechanistic
BUTABARBITAL SODIUM ~ modulates Mechanistic
MIDAZOLAM HYDROCHLORIDE ~ modulates Mechanistic
SANDARACOPIMARIC ACID ? unclear Mechanistic
QUAZEPAM ~ modulates Mechanistic
PHENOBARBITAL ? unclear Mechanistic
PRIMIDONE ~ modulates Mechanistic
ISOGUVACINE ↑ activates Mechanistic
ZOLPIDEM TARTRATE ~ modulates Mechanistic
CHEMBL:CHEMBL2170369 ? unclear Mechanistic
ESTAZOLAM ~ modulates Mechanistic
TOPIRAMATE ~ modulates Mechanistic
ETHCHLORVYNOL ~ modulates Mechanistic
CLORAZEPATE DIPOTASSIUM ~ modulates Mechanistic
ZALEPLON ~ modulates Mechanistic
FLUNITRAZEPAM ~ modulates Mechanistic 4.5 nM (Kd)
BUTABARBITAL ? unclear Mechanistic
THIAMYLAL ? unclear Mechanistic
BUTALBITAL ~ modulates Mechanistic

Showing top 40 of 302 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
OCINAPLON ~ modulates Mechanistic
FLUNITRAZEPAM ~ modulates Mechanistic
PAGOCLONE ? unclear Mechanistic
LORAZEPAM ~ modulates Mechanistic
PRIMIDONE ~ modulates Mechanistic
PICROTOXIN ↓ inhibits Mechanistic
BROMAZEPAM ~ modulates Mechanistic
DEXMEDETOMIDINE HYDROCHLORIDE ? unclear Mechanistic
TOPIRAMATE ~ modulates Mechanistic
ZOLPIDEM TARTRATE ~ modulates Mechanistic
ZOPICLONE ~ modulates Mechanistic
ESZOPICLONE ~ modulates Mechanistic
AZD7325 ~ modulates Mechanistic 0.3 nM (Ki)
&ALPHA;5IA ~ modulates Mechanistic
PRAZEPAM ~ modulates Mechanistic
METHOHEXITAL SODIUM ~ modulates Mechanistic
ACAMPROSATE CALCIUM ~ modulates Mechanistic
DIAZEPAM ~ modulates Mechanistic 17.0 nM (Ki)
RO4938581 ~ modulates Mechanistic
PENTOBARBITAL SODIUM ~ modulates Mechanistic
MEPROBAMATE ↑ activates Mechanistic
FLUMAZENIL ~ modulates Mechanistic 0.7943 nM (Ki)
[18F]FLUOROETHYLFLUMAZENIL ~ modulates Mechanistic
CLOMETHIAZOLE ~ modulates Mechanistic
GANAXOLONE ~ modulates Mechanistic
BRETAZENIL ~ modulates Mechanistic
THIOPENTAL ? unclear Mechanistic
HEXOBARBITAL ? unclear Mechanistic
OXAZEPAM ~ modulates Mechanistic
FLURAZEPAM ? unclear Mechanistic
IMEPITOIN ↑ activates Mechanistic
TRIAZOLAM ~ modulates Mechanistic
BUTALBITAL ~ modulates Mechanistic
ALPRAZOLAM ~ modulates Mechanistic 12.0 nM (EC50)
HALOTHANE ~ modulates Mechanistic
ADIPIPLON ↑ activates Mechanistic
ISOFLURANE ~ modulates Mechanistic
TALBUTAL ~ modulates Mechanistic
CIPEPOFOL ↑ activates Mechanistic
CLORAZEPATE DIPOTASSIUM ~ modulates Mechanistic

Showing top 40 of 264 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
FILOREXANT ↓ inhibits Mechanistic
SUVOREXANT ↓ inhibits Mechanistic
FIRAZOREXTON ↑ activates Mechanistic
RTOXA-43 ↑ activates Mechanistic
JH112 ↓ inhibits Mechanistic
[3H]-ALMOREXANT ↓ inhibits Mechanistic
[3H]SB-674042 ↓ inhibits Mechanistic
OREXIN-B ↑ activates Mechanistic
CHEMBL:CHEMBL1520346 ? unclear Mechanistic
[125I]OREXIN A (HUMAN, MOUSE, RAT) ? unclear Mechanistic
OVEPOREXTON ↑ activates Mechanistic
ORN-0829 HYDRATE ↓ inhibits Mechanistic
TCS 1102 ↓ inhibits Mechanistic
[ALA11, D-LEU15]OREXIN-B ↑ activates Mechanistic
YNT-185 ↑ activates Mechanistic
SB-334867 ↓ inhibits Mechanistic
EMPA ↓ inhibits Mechanistic
COMPOUND 11 [PMID: 15261275] ↓ inhibits Mechanistic
OREXIN-A ↑ activates Mechanistic
ACT-335827 ↓ inhibits Mechanistic
SB-408124 ↓ inhibits Mechanistic
MK-1064 ↓ inhibits Mechanistic
SB-649868 ? unclear Mechanistic
MK-3697 ↓ inhibits Mechanistic
FAZAMOREXANT ↓ inhibits Mechanistic
LEMBOREXANT ↓ inhibits Mechanistic
LSN2424100 ↓ inhibits Mechanistic
SB-410220 ↓ inhibits Mechanistic
SELTOREXANT ↓ inhibits Mechanistic
DARIDOREXANT HYDROCHLORIDE ↓ inhibits Mechanistic
DANAVOREXTON ↑ activates Mechanistic
[3H]-TCS 1102 ↓ inhibits Mechanistic
HTL6641 ↓ inhibits Mechanistic
1-SORA-51 ↓ inhibits Mechanistic
DARIDOREXANT ↓ inhibits Mechanistic
NIVASOREXANT ? unclear Mechanistic
ALMOREXANT ↓ inhibits Mechanistic 13.0 nM (IC50)
SB-674042 ↓ inhibits Mechanistic
CVN45502 ↓ inhibits Mechanistic
COMPOUND 1 [PMID: 33547286] ↑ activates Mechanistic

Showing top 40 of 233 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DARIDOREXANT ↓ inhibits Mechanistic
TCS 1102 ↓ inhibits Mechanistic
FILOREXANT ↓ inhibits Mechanistic
T-516 ↑ activates Mechanistic
OREXIN-A ↑ activates Mechanistic
ACT-335827 ↓ inhibits Mechanistic
MK-3697 ↓ inhibits Mechanistic
ACT-462206 ↓ inhibits Mechanistic
EMPA ↓ inhibits Mechanistic
OVEPOREXTON ↑ activates Mechanistic
RTOXA-43 ↑ activates Mechanistic
FIRAZOREXTON ↑ activates Mechanistic
HTL6641 ↓ inhibits Mechanistic
DANAVOREXTON ↑ activates Mechanistic
SELTOREXANT ↓ inhibits Mechanistic
COMPOUND 1 [PMID: 33547286] ↑ activates Mechanistic
[3H]-TCS 1102 ↓ inhibits Mechanistic
FAZAMOREXANT ↓ inhibits Mechanistic
ORN-0829 HYDRATE ↓ inhibits Mechanistic
CP-1 ↓ inhibits Mechanistic
[3H]EMPA ↓ inhibits Mechanistic
SB-649868 ↓ inhibits Mechanistic
(R)-YNT-3708 ↑ activates Mechanistic
VORNOREXANT ↓ inhibits Mechanistic
SUVOREXANT ↓ inhibits Mechanistic
SB-674042 ↓ inhibits Mechanistic
ALIXOREXTON ↑ activates Mechanistic
[3H]-ALMOREXANT ↓ inhibits Mechanistic
SB-334867 ↓ inhibits Mechanistic
[125I]OREXIN A (HUMAN, MOUSE, RAT) ? unclear Mechanistic
YNT-185 ↑ activates Mechanistic
TCS-OX2-29 ↓ inhibits Mechanistic
CVN45502 ↓ inhibits Mechanistic
[3H]T-516 ↑ activates Mechanistic
LEMBOREXANT ↓ inhibits Mechanistic
[3H]SB-674042 ↓ inhibits Mechanistic
LSN2424100 ↓ inhibits Mechanistic
ALMOREXANT ↓ inhibits Mechanistic
NAG 26 ↑ activates Mechanistic
[ALA11, D-LEU15]OREXIN-B ↑ activates Mechanistic

Showing top 40 of 245 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
HISTAMINE ↑ activates Mechanistic 13.0 nM (EC50)
RISPERIDONE ↓ inhibits Mechanistic 2.6 nM (Ki)
EPINASTINE ↓ inhibits Mechanistic
PYRILAMINE ↓ inhibits Mechanistic 12.59 nM (IC50)
ORPHENADRINE ? unclear Mechanistic
MIZOLASTINE ↓ inhibits Mechanistic
BETAHISTINE ↑ activates Mechanistic
METHAPYRILENE FUMARATE ↓ inhibits Mechanistic
MIANSERIN ? unclear Mechanistic 3.388 nM (IC50)
MEQUITAZINE ↓ inhibits Mechanistic
SERTINDOLE ↓ inhibits Mechanistic 570.0 nM (Ki)
BROMPHENIRAMINE ? unclear Mechanistic
LORATADINE ↓ inhibits Mechanistic
TRIMEPRAZINE ? unclear Mechanistic
BU-E 47 ↓ inhibits Mechanistic
DEXCHLORPHENIRAMINE MALEATE ? unclear Mechanistic
AZELASTINE ↓ inhibits Mechanistic
ASENAPINE ↓ inhibits Mechanistic
BROMODIPHENHYDRAMINE ? unclear Mechanistic
OLOPATADINE HYDROCHLORIDE ↓ inhibits Mechanistic
BEPOTASTINE BESILATE ? unclear Mechanistic
FEXOFENADINE HYDROCHLORIDE ↓ inhibits Mechanistic
PROPIOMAZINE ? unclear Mechanistic
CETIRIZINE HYDROCHLORIDE ↓ inhibits Mechanistic
DIPHENHYDRAMINE ↓ inhibits Mechanistic
ARPROMIDINE ↓ inhibits Mechanistic
PHENIRAMINE ? unclear Mechanistic
QUETIAPINE FUMARATE ↓ inhibits Mechanistic
AZATADINE ? unclear Mechanistic
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic
TRIPROLIDINE ↓ inhibits Mechanistic
PROMETHAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
HYDROXYZINE ↓ inhibits Mechanistic
ILOPERIDONE ? unclear Mechanistic
PEMIROLAST ? unclear Mechanistic
CHLORPHENIRAMINE POLISTIREX ↓ inhibits Mechanistic
DIMETHINDENE ↓ inhibits Mechanistic 0.6918 nM (Ki)
VAPITADINE ? unclear Mechanistic
ARIPIPRAZOLE LAUROXIL ↓ inhibits Mechanistic
BRILAROXAZINE ? unclear Mechanistic

Showing top 40 of 374 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LURASIDONE HYDROCHLORIDE ? unclear Mechanistic
ESMIRTAZAPINE ? unclear Mechanistic
PERGOLIDE ↑ activates Mechanistic
XANOMELINE ↓ inhibits Mechanistic
BROLAMFETAMINE ↑ activates Mechanistic 41.0 nM (Ki)
BRL-15572 ↑ activates Mechanistic
ARIPIPRAZOLE LAUROXIL ↓ inhibits Mechanistic
MIANSERIN ↓ inhibits Mechanistic
[3H]8-OH-DPAT ↑ activates Mechanistic
OLANZAPINE ↓ inhibits Mechanistic
SB 228357 ↓ inhibits Mechanistic
5-HYDROXYTRYPTAMINE ↑ activates Mechanistic
HALOPERIDOL LACTATE ↓ inhibits Mechanistic
METHYLERGONOVINE ↑ activates Mechanistic
QUIPAZINE ↑ activates Mechanistic
ASENAPINE ↓ inhibits Mechanistic
FLUPHENAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
LUMATEPERONE ↓ inhibits Mechanistic
TRIFLUOPERAZINE ↓ inhibits Mechanistic
KETANSERIN ↓ inhibits Mechanistic
LOXAPINE ↓ inhibits Mechanistic
VER-3323 ↑ activates Mechanistic
SARPOGRELATE ↓ inhibits Mechanistic
BREXPIPRAZOLE ↓ inhibits Mechanistic
EPLIVANSERIN ? unclear Mechanistic
PROMAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
TRAZODONE ↓ inhibits Mechanistic
MOLINDONE HYDROCHLORIDE ↓ inhibits Mechanistic
BLONANSERIN ↓ inhibits Mechanistic
MOLINDONE ↓ inhibits Mechanistic
9-OH-RISPERIDONE ↓ inhibits Mechanistic
PRUVANSERIN ↓ inhibits Mechanistic
QUETIAPINE FUMARATE ↓ inhibits Mechanistic
NEFAZODONE ↓ inhibits Mechanistic
BW723C86 ↑ activates Mechanistic
MESORIDAZINE ↓ inhibits Mechanistic
ORG 12962 ↑ activates Mechanistic
FLIBANSERIN ↓ inhibits Mechanistic
LP-12 ↑ activates Mechanistic
MESORIDAZINE BESYLATE ↓ inhibits Mechanistic

Showing top 40 of 362 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AZD7325 ↓ inhibits Mechanistic
UCM 549 ↓ inhibits Mechanistic
S20928 ↓ inhibits Mechanistic
IIK7 ↑ activates Mechanistic
MELATONIN ↑ activates Mechanistic 0.4 nM (Ki)
S26284 ↑ activates Mechanistic
S24773 ↑ activates Mechanistic
AGOMELATINE ↑ activates Mechanistic 0.06 nM (Ki)
2-METHOXY-&ALPHA;,&BETA;-DIDEHYDRO-AGOMELATINE ↑ activates Mechanistic
RAMELTEON ↑ activates Mechanistic 0.0138 nM (Ki)
UCSF4226 ↑ activates Mechanistic
TASIMELTEON ↑ activates Mechanistic
GR 196429 ↑ activates Mechanistic
UCM 793 ↑ activates Mechanistic
PIROMELATINE ↑ activates Mechanistic
S24014 ↑ activates Mechanistic
S22153 ↓ inhibits Mechanistic
EFPPEA ↑ activates Mechanistic
UCSF3384 ↑ activates Mechanistic
LUZINDOLE ↓ inhibits Mechanistic
[125I]SD6 ↑ activates Mechanistic
2-[125I]MELATONIN ↑ activates Mechanistic
4P-PDOT ↓ inhibits Mechanistic
5-HEAT ↑ activates Mechanistic
UCM 724 ↓ inhibits Mechanistic
6-CL-MLT ↑ activates Mechanistic
N-[2-(2-IODO-5-METHOXY-1H-INDOL-3-YL)ETHYL]ACETAMIDE ↑ activates Mechanistic
UCM1341 ↑ activates Mechanistic
S26131 ↓ inhibits Mechanistic
AAE-M-PBP-AMINE ↑ activates Mechanistic
6-HYDROXYMELATONIN ↑ activates Mechanistic
GR 128107 ↑ activates Mechanistic
K185 ↓ inhibits Mechanistic
ICOA-13 ↑ activates Mechanistic
TIK-301 ? unclear Mechanistic
DIFLUOROAGOMELATINE ↑ activates Mechanistic
LY 156735 ↑ activates Mechanistic
UCSF7447 ↓ inhibits Mechanistic
CBOBNEA ↑ activates Mechanistic
CHEMBL127565 ↓ inhibits Mechanistic 492.0 nM (Ki)

Showing top 40 of 207 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LUZINDOLE ↓ inhibits Mechanistic
S20928 ↓ inhibits Mechanistic
UCSF3384 ↑ activates Mechanistic
ISOAMYL-AGOMELATINE ↑ activates Mechanistic
TASIMELTEON ↑ activates Mechanistic
AGOMELATINE ↑ activates Mechanistic 0.27 nM (Ki)
S22153 ↑ activates Mechanistic
IIK7 ↑ activates Mechanistic
[125I]SD6 ↑ activates Mechanistic
BOMPPA ↑ activates Mechanistic
4P-PDOT ↓ inhibits Mechanistic
UCM 549 ↓ inhibits Mechanistic
(HYDROXYMETHYLPHENYL)AGOMELATINE ↓ inhibits Mechanistic
UCSF7447 ↑ activates Mechanistic
GR 196429 ↑ activates Mechanistic
S26284 ↑ activates Mechanistic
S26131 ↓ inhibits Mechanistic
ICOA-13 ↑ activates Mechanistic
MELATONIN ↑ activates Mechanistic 0.3 nM (Ki)
5-HEAT ↓ inhibits Mechanistic
UCM1341 ↑ activates Mechanistic
S24014 ↑ activates Mechanistic
PIROMELATINE ↑ activates Mechanistic
2-[125I]MELATONIN ↑ activates Mechanistic
UCM 765 ↑ activates Mechanistic
S24773 ↑ activates Mechanistic
GR 128107 ↑ activates Mechanistic
CIFEA ↑ activates Mechanistic
VINCRISTINE ? unclear Mechanistic
2-(INDOLIN-1YL)-MELATONIN ↓ inhibits Mechanistic
LY 156735 ↑ activates Mechanistic
N-[2-(2-IODO-5-METHOXY-1H-INDOL-3-YL)ETHYL]ACETAMIDE ↑ activates Mechanistic
UCM1014 ↑ activates Mechanistic
6-HYDROXYMELATONIN ↑ activates Mechanistic
[125I]S70254 ↑ activates Mechanistic
RAMELTEON ↑ activates Mechanistic 0.045 nM (Ki)
UCM 724 ↓ inhibits Mechanistic
UCSF4226 ↑ activates Mechanistic
6-CL-MLT ↑ activates Mechanistic
DH97 ↓ inhibits Mechanistic

Showing top 40 of 220 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Insomnia / Sleep Disorders: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT06655883 Phase: 3 Started: 2025-10-09

People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to ...

NCT07542756 Phase: 4 Started: 2026-05-01

The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better...

NCT07420816 Phase: 2 Started: 2026-08-05

The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.

NCT07695246 Phase: N/A Started: 2026-08-01

This study tests the efficacy of cognitive behavioural therapy for insomnia (CBT-I) with or without adjunct melatonin in older adults with insomnia. Adults aged 60 or above with chronic insomnia will be randomly assigned to one of three groups: (1) CBT-I plus nightly melatonin, (2) CBT-I plus nightl...

NCT07735390 Phase: N/A Started: 2024-09-13

This study aims to evaluate the clinical effectiveness of Traditional Chinese Medicine (TCM) in treating sleep disorders, specifically chronic insomnia. While conventional TCM treatments often rely heavily on subjective patient feedback, this clinical trial incorporates objective diagnostic tools, i...

NCT06511011 Phase: 2 Started: 2025-09-25

This is a randomized, double-blinded, placebo-controlled clinical trial. Eligible participants will randomized into either treatment group (CM granules) or placebo group (placebo granules) for 6 weeks, followed by a post-treatment visit at week 9. The primary outcome is the change in Pittsburgh Slee...

NCT05823844 Phase: 4 Started: 2023-05-01

The study is a parallel group, double blind, randomized trial. Subjects will be recruited from individuals undergoing elective surgery for orthopedic, abdominal, urologic, gynecologic or spine reasons. Out of 92 subjects, one experimental group of 46 subjects will receive 20 mg Suvorexant beginning ...

NCT07357779 Phase: N/A Started: 2026-01-20

The purpose of this study is to evaluate the clinical and cost-effectiveness of an intelligent therapy based on digital cognitive behavioral therapy for insomnia disorders

NCT05525637 Phase: 3 Started: 2021-12-17

The main purpose of this study is to assess efficacy and safety of YZJ-1139 in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

NCT06671470 Phase: 1 Started: 2024-08-22

Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with YZJ-1139 tablets in healthy subjects.

NCT06671444 Phase: 1 Started: 2024-06-03

Objective: 1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment. 2. To evaluate the safety of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment.

NCT05840822 Phase: 3 Started: 2024-05-16

Insomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep. Consequences of insomnia include daytime sleepiness, poor memory function, decline in concentration with negative impacts on social and work activities. Although medic...

NCT06975514 Phase: 3 Started: 2025-03-25

The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

NCT06953869 Phase: 3 Started: 2025-04-21

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.

NCT03668041 Phase: 3 Started: 2021-02-25

Many Veterans with posttraumatic stress disorder (PTSD) have trouble sleeping or have frequent nightmares. So far, no medication has been approved for treatment of insomnia in PTSD. The purpose of this research study is to find out if taking medications called trazodone or eszopiclone can help decre...


Agents Found By Disease-Level Search

Searched directly from “Insomnia / Sleep Disorders” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

35 agents shown (approved or with trial evidence) — 33 not found by the gene-target search above.

Suvorexant

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02729714 NCT02849184

Zolpidem

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00440323 NCT00662155

Internet-delivered CBT for InsomniaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04936321

Internet-delivered CBT for Pain ManagementNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04936321

GabapentinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01421264

Lemborexant 10 MGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06823752

CBT for Menopausal Insomnia (CBTMI)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02092844

TIAN WANG BU XIN DANNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02319993

Suan Tzao Ren TangNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02319993

Latin DanceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06844981

CefalyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04838067

CBTINOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05965609

MRTINOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05965609

Heart-rate variability biofeedback interventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06281145

SleepStyle 200 Auto Series with SensAwakeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00811213

SleepStyle 200 Auto Series with out SensAwakeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00811213

Xbox 360 KinectNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03906396

Night Time TeaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05478980

Control TeaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05478980

i-Sleep & BioClockNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06023693

SHUTiNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03390114

WELT-IPNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05822999

SHUTi (Sleep Health Using the Internet)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03213132

Sleep ALL NightNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05866887

Food-Grown MagnesiumNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05825209

Microcrystalline celluloseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05825209

GABANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04857021

In Person CBT-INOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06867666

CBT-I via COASTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06867666

Sleep OptimizationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05561829

Stimulus Control TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05561829

Sleep Intervention for PTSD (SIP).NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00734799

Modified Suan ZaoRen Tang-TianWang BuXin DanNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06511011

Nightmare Deconstruction and ReprocessingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06399874

NightWareNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06399874

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.